DNLI Research and Charts

DNLI - Denali Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-02-05 (Delayed quote data 2025-01-06)

Last 19.82	Change ⇓ -1.44 (-6.77%)	Volume 1,607,372
	Open 21.10	High 21.39	Low 19.73

8EMA (Daily) 20.77	40EMA (Daily) 23.32	50EMA (Daily) 23.76	STO (Daily) 14.031	MACD Hist (Daily) -0.052
8EMA (Weekly) 22.386	40EMA (Weekly) 23.62	50EMA (Weekly) 23.54	STO (Weekly) 4.077	MACD Hist (Weekly) -1.889


Company Profile
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.